Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Takara Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 12, 2020

            Details:

            PanCELLa agreement marks Merck’s first CRISPR license for bioproduction . Takara Bio USA agreement gives access to Merck’s CRISPR integration and vector technologies for Takara’s vector products and cell engineering services.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: REMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 16, 2020

            Details:

            In the collaboration, GenScript ProBio allowed REMD to use its SMAB bispecific antibody platform to develop novel cancer immunotherapy drugs. GenScript ProBio will support REMD with the selection and development of bispecific antibody candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $5.0 million Upfront Cash: $5.0 million

            Deal Type: Acquisition September 10, 2020

            Details:

            The acquisitions are expected to enable Ligand to secure new license agreements with expanded economics as a result of the addition of tools and intellectual property that Ligand can now offer to partners.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mono- and Bispecific human antibodies

            Therapeutic Area: Oncology Product Name: OmniAb

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ligand Pharmaceuticals

            Deal Size: $7.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 10, 2020

            Details:

            The acquisition will strengthen company's OmniAb® technology platform. Potential for two approvals of OmniAb-derived antibodies in 2021 with expected new royalty streams to Ligand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $85.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 29, 2020

            Details:

            Financing proceeds support identification of novel therapeutic targets and enable genomic medicine programs across a wide range of therapeutic areas

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-based gene therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

            Deal Size: $225.0 million Upfront Cash: $125.0 million

            Deal Type: Licensing Agreement April 01, 2020

            Details:

            Ultragenyx granted Daiichi Sankyo license to intellectual property, including know-how and patent applications, with respect to its HeLa manufacturing platform for AAV-based gene therapy products.